Glofitamab in relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL): durable complete responses and manageable safety observed at clinically relevant doses in Phase I dose escalation

被引：0
|
作者：
Hutchings, M. [1 ]
Morschhauser, F. [2 ]
Iacoboni, G. [3 ]
Carlo-Stella, C. [4 ]
Offner, F. C. [5 ]
Sureda, A. [6 ]
Salles, G. [7 ,8 ]
Martinez-Lopez, J. [9 ]
Crump, M. [10 ]
Lundberg, L. [11 ]
Dixon, M. [12 ]
Kwan, A. [13 ]
Wei, M. C. [13 ]
Broeske, A-M E. [14 ]
Carlile, D. [12 ]
O'Hear, C. [13 ]
Dickinson, M. J. [15 ,16 ]
机构：
[1] Rigshosp Copenhagen, Dept Oncol, Copenhagen, Denmark
[2] Ctr Hosp Reg Univ Lille, Lille, France
[3] Vall dHebron Univ Hosp, Barcelona, Spain
[4] Humanitas Univ, Milan, Italy
[5] Univ Ziekenhuis Gent, Ghent, Belgium
[6] Inst Catala Oncol Hospitalet, Barcelona, Spain
[7] Hosp Civils Lyon, Pierre Benite, France
[8] Univ Claude Bernard, Pierre Benite, France
[9] Hosp Univ 12 Octubre H12O, Madrid, Spain
[10] Princess Margaret Hosp, Toronto, ON, Canada
[11] F Hoffmann La Roche Ltd, Basel, Switzerland
[12] Roche Prod Ltd, Welwyn Garden City, Herts, England
[13] Genentech Inc, San Francisco, CA 94080 USA
[14] Roche Pharma Res & Early Dev, Roche Innovat Ctr, Penzberg, Germany
[15] Royal Melbourne Hosp, Melbourne, Vic, Australia
[16] Univ Melbourne, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷 / SUPPL 4期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
226
引用
收藏
页码：58 / 59
页数：2
相关论文
共 50 条
  • [31] Maximum Tolerated Dose (MTD) and Safety Profile from Phase I Study of MT-3724 (CD20 targeted immunotoxin) in Relapsed/Refractory (R/R) Non-Hodgkin B-Cell Lymphoma (NHL)
    Fanale, Michelle A.
    Park, Steven I.
    Valacer, David J.
    Higgins, Jack
    Sloan, John Mark
    Younes, Anas
    Hamlin, Paul A.
    BLOOD, 2017, 130
  • [32] R2: Preliminary Results of a Phase II Study of Lenalidomide and Rituximab in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (NHL)
    DeRook, Ian
    Odonnell, Robert T.
    Noble, B.
    Quirch, C.
    Tuscano, Joseph
    BLOOD, 2008, 112 (11) : 1052 - 1052
  • [33] R2: Preliminary Results of a Phase II Study of Lenalidomide and Rituximab in Relapsed Refractory Indolent Non-Hodgkin's Lymphoma (NHL).
    Dutia, Mrinal
    DeRoock, Ian
    Chee, Karen
    O'donnell, Robert
    Quirch, Christine
    Reed-Pease, Christine
    Tuscano, Joseph
    BLOOD, 2009, 114 (22) : 670 - 670
  • [34] Zevalin dose-escalation followed by high-dose beam and autotransplant in CD20+relapsed or refractory non-Hodgkin lymphoma (NHL)
    Winter, JN
    Inwards, D
    Erwin, W
    Wiseman, G
    Rademaker, A
    Patton, DR
    Williams, S
    Tallman, MS
    Mehta, J
    Singhal, S
    Micallef, I
    Multani, P
    Zimmer, M
    Spies, S
    Molina, A
    White, C
    Gordon, LI
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2004, 10 (02) : 28 - 29
  • [35] Phase Ib Dose Escalation Trial of Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
    Andreadis, Charalambos
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (01): : XVIII - XIX
  • [36] Phase I study of CC-90010, a reversible, oral BET inhibitor in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)
    Moreno, V.
    Brana, I.
    Sepulveda Sanchez, J. M.
    Vieito Villar, M.
    Hernandez Guerrero, T.
    Doger, B.
    Saavedra, O.
    Pinto, A.
    Carlo Stella, C.
    Italiano, A.
    Michot, J-M.
    Musuraca, G.
    Sarmiento, R.
    De Alvaro, J.
    Zuraek, M.
    Sanchez-Perez, T.
    Aronchik, I.
    Filvaroff, E.
    Hanna, B.
    Nikolova, Z.
    ANNALS OF ONCOLOGY, 2020, 31 : S5 - S5
  • [37] Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed By Autologous Stem Cell Transplant (ASCT) for Chemoresistant or HighRisk Relapsed/Refractory Non-Hodgkin Lymphoma (NHL)
    Maakaron, Joseph
    Zhao, Qiuhong
    Balakrishna, Jayalakshmi Panicker
    Puto, Marcin
    Ferguson, Wesley
    Penza, Sam
    Brammer, Jonathan E.
    Maddocks, Kami J.
    Efebera, Yvonne A.
    Saad, Ayman
    Jaglowski, Samantha
    William, Basem M.
    BLOOD, 2021, 138
  • [38] Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)
    Abrisqueta, Pau
    Sancho, Juan-Manuel
    Cordoba, Raul
    Persky, Daniel O.
    Andreadis, Charalambos
    Huntington, Scott F.
    Carpio, Cecilia
    Giles, Daniel Morillo
    Wei, Xin
    Li, Ying Fei
    Zuraek, Marlene
    Burgess, Michael R.
    Hege, Kristen
    Martin, Alejandro
    BLOOD, 2019, 134
  • [39] Population Pharmacokinetics and CD20 Binding Dynamics for Mosunetuzumab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL)
    Bender, Brendan C.
    Li, Chi-Chung
    Marchand, Mathilde
    Turner, David C.
    Li, Feifei
    Vadhavkar, Shweta
    Wang, Bei
    Deng, Rong
    Lu, James
    Jin, Jin
    Li, Chunze
    Yin, Shen
    Wei, Michael C.
    Chanu, Pascal
    BLOOD, 2023, 142
  • [40] Clofarabine (CLO) Has Single Agent Activity in Relapsed and Refractory Non-Hodgkin Lymphoma (NHL) Including Rituximab (R)-Refractory Patients (pts)
    Nabhan, Chadi
    Bitran, Jacob David
    Fried, Walter
    Galvez, Angel G.
    Magid, Laura
    Tolzien, Kathy
    Dewey, Wendy
    Venugopal, Parameswaran
    BLOOD, 2009, 114 (22) : 380 - 380
12345